BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 32922387)

  • 1. HLA-G Neo-Expression on Tumors.
    Loustau M; Anna F; Dréan R; Lecomte M; Langlade-Demoyen P; Caumartin J
    Front Immunol; 2020; 11():1685. PubMed ID: 32922387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-G: A New Immune Checkpoint in Cancer?
    Krijgsman D; Roelands J; Hendrickx W; Bedognetti D; Kuppen PJK
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunosuppressive molecule HLA-G and its clinical implications.
    González A; Rebmann V; LeMaoult J; Horn PA; Carosella ED; Alegre E
    Crit Rev Clin Lab Sci; 2012; 49(3):63-84. PubMed ID: 22537084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular pathways: human leukocyte antigen G (HLA-G).
    Curigliano G; Criscitiello C; Gelao L; Goldhirsch A
    Clin Cancer Res; 2013 Oct; 19(20):5564-71. PubMed ID: 23897901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human leukocyte antigen-G (HLA-G) as a marker for diagnosis, prognosis and tumor immune escape in human malignancies.
    Yie SM; Hu Z
    Histol Histopathol; 2011 Mar; 26(3):409-20. PubMed ID: 21210353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies.
    Morandi F; Airoldi I
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-G: Too Much or Too Little? Role in Cancer and Autoimmune Disease.
    Martín-Villa JM; Vaquero-Yuste C; Molina-Alejandre M; Juarez I; Suárez-Trujillo F; López-Nares A; Palacio-Gruber J; Barrera-Gutiérrez L; Fernández-Cruz E; Rodríguez-Sainz C; Arnaiz-Villena A
    Front Immunol; 2022; 13():796054. PubMed ID: 35154112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo evidence that secretion of HLA-G by immunogenic tumor cells allows their evasion from immunosurveillance.
    Loumagne L; Baudhuin J; Favier B; Montespan F; Carosella ED; Rouas-Freiss N
    Int J Cancer; 2014 Nov; 135(9):2107-17. PubMed ID: 24623585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of HLA-G/KIR2DL4 in Breast Cancer Immune Microenvironment.
    Zheng G; Jia L; Yang AG
    Front Immunol; 2022; 13():791975. PubMed ID: 35185887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients.
    Hiraoka N; Ino Y; Hori S; Yamazaki-Itoh R; Naito C; Shimasaki M; Esaki M; Nara S; Kishi Y; Shimada K; Nakamura N; Torigoe T; Heike Y
    Cancer Sci; 2020 Aug; 111(8):3057-3070. PubMed ID: 32495519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges.
    Lin A; Yan WH
    Front Immunol; 2018; 9():2164. PubMed ID: 30319626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?
    Attia JVD; Dessens CE; van de Water R; Houvast RD; Kuppen PJK; Krijgsman D
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33213057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-G/sHLA-G and HLA-G-Bearing Extracellular Vesicles in Cancers: Potential Role as Biomarkers.
    Li P; Wang N; Zhang Y; Wang C; Du L
    Front Immunol; 2021; 12():791535. PubMed ID: 34868081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.
    Algarra I; García-Lora A; Cabrera T; Ruiz-Cabello F; Garrido F
    Cancer Immunol Immunother; 2004 Oct; 53(10):904-10. PubMed ID: 15069585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The non-classical antigens of HLA-G and HLA-E as diagnostic and prognostic biomarkers and as therapeutic targets in transplantation and tumors.
    Seliger B
    Clin Transpl; 2013; ():465-72. PubMed ID: 25095542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dual role of HLA-G in cancer.
    Rouas-Freiss N; Moreau P; LeMaoult J; Carosella ED
    J Immunol Res; 2014; 2014():359748. PubMed ID: 24800261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of HLA-G in tumors and upon COVID-19 infection.
    Seliger B
    Hum Immunol; 2024 May; 85(3):110792. PubMed ID: 38555250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges.
    Lin A; Yan WH
    Front Immunol; 2021; 12():698677. PubMed ID: 34276691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-G regulators in cancer medicine: an outline of key requirements.
    Zidi I; Ben Amor N
    Tumour Biol; 2011 Dec; 32(6):1071-86. PubMed ID: 21792710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.